John Wyatt, a Nashville-area sales leader with 20+ years of experience launching, marketing and selling aesthetic medical devices, joined the Cohera Medical, Inc. sales team.
RALEIGH, NC, February 16, 2017 – Cohera Medical, Inc., a leading innovator and developer of absorbable surgical adhesives and sealants, announced today the hiring of John Wyatt as Vice President of Sales.
“We are thrilled to welcome John to the Cohera team,” said Patrick Daly, President and CEO of Cohera Medical, Inc. “John’s experience in the aesthetic medical device and biopharmaceutical industry will be pivotal to Cohera. With the only FDA-approved adhesive for internal use and with our excellent clinical outcomes, John is poised to grow the TissuGlu® Surgical Adhesive business and help make drain free Tummy Tucks standard of care. His wealth of knowledge in the space and his relationships with the key opinion leaders in plastic surgery, make John the right person to lead our sales team”.
Prior to Joining Cohera, Mr. Wyatt served in several senior leadership roles in the aesthetic space, where he has spent over 19 years of his career. He recently worked for Kythera Biopharmaceuticals, a company owned by Allergan, focused on developing and launching Kybella, the only FDA-approved injectable treatment that destroys fat cells under the chin to improve your profile. Additionally, Mr. Wyatt helped lead the sales team at Mentor Worldwide, LLC, a Johnson & Johnson Company, launch numerous implantable mammary devices and capital equipment for lipoplasty surgery.
“This is an exciting time to join the Cohera team,” said Mr. Wyatt. “Both TissuGlu Surgical Adhesive and Cohera’s pipeline product, Sylys Surgical Sealant, have enormous potential to revolutionize surgical procedures for both surgeons and patients.”
Mr. Wyatt received his BBA from the University of Oklahoma, majoring in Marketing with a minor in Economics. He and his family are located in Nashville, TN.
For more information about the Cohera Medical Leadership team, TissuGlu Surgical Adhesive, or Sylys Surgical Sealant, please visit www.CoheraMedical.com.
Cohera Medical, Inc.
Sr. Marketing Manager
(984) 222-0400 (office)
Senior Account Executive
(919) 926-3628 (office)
About Cohera Medical
Cohera Medical, Inc. is a growing medical device company that is developing and commercializing a line of surgical adhesives and sealants. Cohera Medical’s products are based on a unique chemical design that is resorbable, non-toxic, and easy-to-use. The Company’s lead product, TissuGlu Surgical Adhesive, is indicated for use in the U.S. for the approximation of tissue planes in abdominoplasty procedures. Refer to the complete Directions for Use information available at TissuGlu.com for a full description of use information including the contraindications, warnings, precautions, benefits, and risks of use of TissuGlu Surgical Adhesive. TissuGlu is currently approved for sale in the EU for the approximation of tissue layers where subcutaneous dead space exists between the tissue planes in large flap surgical procedures such as abdominoplasty and is being utilized in Europe to eliminate drains or reduce complications in patients undergoing large flap surgical procedures such as abdominoplasty, mastectomy, ventral hernia repair, decubitus and latissimus dorsi flap procedures. The Company’s second product under development, Sylys® Surgical Sealant, the first synthetic sealant designed specifically to help reduce anastomotic leaks, has received CE Mark approval in Europe as an adjunct to standard closure in ileostomy reversal procedures. TissuGlu and Sylys are the first products in a pipeline of technology that includes adhesives for surgical mesh fixation, meniscal repair and other orthopedic indications. Sylys and the other Cohera Medical products are currently available for investigational use only and have not yet been approved for sale by the Food and Drug Administration (FDA) in the U.S..
Certain statements made throughout this press release that are not historical facts contain forward-looking statements regarding the Company’s future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements.